Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has significantly expanded its oncology…
Read More
Traumatic brain injury and Alzheimer’s disease, common neuroinflammatory pathologies and therapeutic potential
Traumatic brain injury (TBI) represents a formidable global public health challenge, impacting an estimated 69 million individuals each year across…
Read More
Beyond PD-1: The Drugs Reshaping Cancer Treatment at ASCO 2026
The biomedical sector is once again experiencing a vibrant resurgence, marked by robust investment, strategic mergers and acquisitions (M&A), and…
Read More
Eli Lilly’s Retatrutide Shows Unprecedented Weight Loss, But Increased Side Effects Raise Tolerability Concerns
Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…
Read More
Salesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
In a significant move underscoring the escalating competition in the life sciences technology sector, Salesforce announced that over 140 life…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
Rubedo Life Sciences, an AI-driven biotech startup focused on longevity, has announced positive preliminary results from its Phase 1b/2a study…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
Across the global pharmaceutical landscape, a staggering number of potentially life-changing therapies for rare diseases lie dormant, gathering dust on…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…
Read MoreYOU MAY HAVE MISSED
